Sirnaomics Announces Interim Results for STP705 in Phase IIb Study for isSCC
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the interim results of part...
Company
Henlius Biotech Initiates Phase I Trial for HLX60 in Australia
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase...
China Meheco to Import and Distribute Pfizer’s Paxlovid in Mainland China
China Meheco Group Co., Ltd (SHA: 600056) has announced an agreement with US major Pfizer...
Zylox-Tonbridge Receives NMPA Approval for ZYLOX Octoplus Vena Cava Filter
China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced...
Innovent Biologics Collaborates with LG Chem for Tigulixostat in China
China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South...
Alternative Bio Completes $15M Seed Round to Advance Cancer Therapeutics
Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD...
Shanghai Pharmaceuticals Partners with HKSTP for Biomedicine Cultivation Program
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), Shanghai Biomedical Frontier Industry Innovation Center Co., Ltd, and...
111 Inc. Begins Online Sales of Pfizer’s Paxlovid in China
China-based online pharmacy 111 Inc. (NASDAQ: YI) reportedly initiated online retail sales of Pfizer Inc.’s...
Biosion and ImmunoGen Collaborate on Cancer ADCs
China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the...
Abcam and Wuxi Diagnostics Expand Partnership into Companion Diagnostics
UK-headquartered Abcam plc. and China-based Wuxi Diagnostics have expanded their partnership to dive deep into...
Henlius Biotech Partners with Medilink for Global ADC Development
Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with Suzhou-based Medilink Therapeutics, obtaining...
Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study
Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study...
Lifetech Scientific Completes Enrollment for IBS Coronary Stent Phase II Study
China-based Lifetech Scientific Corporation (HKG: 1302) announced that all patients have been enrolled in a...
ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...
Jiangsu Recbio’s COVID-19 Vaccine ReCOV Shows Superiority in Phase II Trial
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the positive results of...
Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting
China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...
Cryofocus Biotechnology’s RDN System Gains FDA Breakthrough Therapy Designation
Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd’s in-house developed Cryofocus RDN System, a...
Cutia Therapeutic Plans IPO on Hong Kong Stock Exchange
China-based dermatology specialist Cutia Therapeutic announced plans to make an initial public offering (IPO) to...
Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202
China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...
Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first...